1307853-51-5

Basic information

• Product Name: 2-butyl-4-chloro-1-({2'-[1-(p-methoxybenzyl)-1H-tetrazol-5-yl]-biphenyl-4-yl}-methyl)imidazole-5-carbaldehyde
• Synonyms: 2-butyl-4-chloro-1-({2'-[1-(p-methoxybenzyl)-1H-tetrazol-5-yl]-biphenyl-4-yl}-methyl)imidazole-5-carbaldehyde
• CAS NO: 1307853-51-5
• Molecular Weight: 541.052
• Mol File: 1307853-51-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-butyl-4-chloro-1-({2'-[1-(p-methoxybenzyl)-1H-tetrazol-5-yl]-biphenyl-4-yl}-methyl)imidazole-5-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-butyl-4-chloro-1-({2'-[1-(p-methoxybenzyl)-1H-tetrazol-5-yl]-biphenyl-4-yl}-methyl)imidazole-5-carbaldehyde(1307853-51-5)
• EPA Substance Registry System: 2-butyl-4-chloro-1-({2'-[1-(p-methoxybenzyl)-1H-tetrazol-5-yl]-biphenyl-4-yl}-methyl)imidazole-5-carbaldehyde(1307853-51-5)

Safety Data

• Hazardous Substances Data: 1307853-51-5(Hazardous Substances Data)

Upstream product

• 824-94-2 p-methoxybenzyl chloride 
• 2393-23-9 4-methoxy-benzylamine 
• 98-88-4 benzoyl chloride 
• 41882-10-4 N-(4-methoxybenzyl)benzamide 
• 1307853-40-2 5-[4'-(bromomethyl)biphenyl-2-yl]-1-(p-methoxybenzyl)-1H-tetrazole 
• 83857-96-9 2-n-butyl-4-chloro-1H-imidazol-5-carboxaldehyde 
• 1307853-38-8 {2'-[1-(p-methoxybenzyl)-1H-tetrazol-5-yl]biphenyl-4-yl}-methanol 
• 1301606-98-3 {2'-{1-(p-methoxybenzyl)-1H-tetrazol-5-yl}biphenyl-4-yl}methyl acetate 
• 512182-38-6 1-(p-methoxybenzyl)-5-phenyl-1H-tetrazole 
• 18039-42-4 5-Phenyl-1H-tetrazole 

Downstream Products

• 1307853-52-6 2-butyl-4-chloro-1-({2'-[1-(p-methoxybenzyl)-1H-tetrazol-5-yl]-biphenyl-4-yl}-methyl)imidazole-5-methanol 
• 114798-36-6 2-n-Butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxaldehyde 
• 114798-26-4 lorsartan 

Relevant articles and documents

Synthesis of angiotensin II receptor blockers by means of a catalytic system for C-H Activation

A highly efficient catalytic system for C-H activation has been worked out that involves inexpensive RuCl3·xH2O and a specific amount of PPh3. This procedure has been successfully applied to a practical synthesis of angiotensin II receptor blockers (ARBs). The residual ruthenium that existed in the reaction mixture was thoroughly removed by treatment with properly selected metal scavengers. The new process permits ready access to the important class of drugs in a highly atom-economical and sustainable manner (Figure presented).